MedTrace Logo

A Study on the Safety and Tolerability of RGL-193 in Patients With Advanced Parkinson's Disease

NCT06195124 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-03-15

No results posted yet for this study

Summary

A safety study in patients with Parkinson's disease.

Conditions

  • Advanced Parkinson's Disease

Interventions

DRUG

RGL-193（low-dose）

Each side of the putamen received 150 μL of RGL-193, with a unilateral dose of 1.5×10\^11 VG and a bilateral dose of 3.0×10\^11 VG.

DRUG

RGL-193（high-dose）

Each side of the putamen received 200 μL of RGL-193, with a unilateral dose of 5.0×10\^11 VG and a bilateral dose of 1.0×10\^12 VG.

Sponsors & Collaborators

  • Shanghai Regenelead Therapies Co., Ltd.

    collaborator INDUSTRY

  • Second Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Chun-Feng Liu, MD · Second Affiliated Hospital of Soochow University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-31
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06195124 on ClinicalTrials.gov